STSA-1002 injection

DRUG6 trials

Sponsors

Staidson (Beijing) Biopharmaceuticals Co., Ltd

Conditions

Acute Respiratory Distress SyndromeAcute Respiratory Distress Syndrome (ARDS)HealthyHealthy Subject

Phase 1

The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects

CompletedNCT05032144

Staidson (Beijing) Biopharmaceuticals Co., LtdHealthy

Start: 2021-09-28End: 2022-03-31Updated: 2022-04-11

The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects

CompletedNCT05166837

Staidson (Beijing) Biopharmaceuticals Co., LtdHealthy

Start: 2022-01-10End: 2023-01-12Updated: 2023-12-20

A Study of STSA-1002 in Healthy Subjects

CompletedNCT05497635

Staidson (Beijing) Biopharmaceuticals Co., LtdHealthy Subject

Start: 2022-10-14End: 2023-04-06Updated: 2023-04-18

A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects

TerminatedNCT05559125

Staidson (Beijing) Biopharmaceuticals Co., LtdHealthy Subject

Start: 2022-11-08End: 2024-03-26Updated: 2024-05-22

To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

CompletedNCT06038916

Staidson (Beijing) Biopharmaceuticals Co., LtdAcute Respiratory Distress Syndrome

Start: 2023-12-09End: 2025-04-27Updated: 2025-07-11

Phase 3

To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

RecruitingNCT07208591

Staidson (Beijing) Biopharmaceuticals Co., LtdAcute Respiratory Distress Syndrome (ARDS)

Start: 2025-10-31End: 2026-10-31Target: 406Updated: 2026-01-02

Related Papers

Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of STSA-1002, recombinant anti-human C5a fully human monoclonal antibody, in a randomized, first-in-human phase I study in healthy adults

Frontiers in Pharmacology2026-06-18